Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

Antibody-based drugs, which now represent the dominant biologic therapeutic modality, are used to modulate disparate signaling pathways across diverse disease indications. One fundamental premise that has driven this therapeutic antibody revolution is the belief that each monoclonal antibody exhibit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	mAbs 2021-01, Vol.13 (1), p.1999195-1999195
Hauptverfasser:	Cunningham, Orla, Scott, Martin, Zhou, Zhaohui Sunny, Finlay, William J.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibody epitope paratope pharmacokinetics polyreactivity polyspecificity Review specificity therapeutic toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!